AKEBIA THERAPEUTICS INC (AKBA) Stock Price, Quote, News and Overview
NASDAQ:AKBA - Nasdaq - US00972D1054 - Common Stock - Currency: USD
AKBA Quote, Performance and Key Statistics
1.8
-0.11 (-5.76%)
The current stock price of AKBA is 1.8 USD. In the past month the price decreased by -24.69%. In the past year, price increased by 33.33%.
AKBA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AKBA
Company Profile
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 167 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). The company utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Company Info
AKEBIA THERAPEUTICS INC
245 First Street
Cambridge MASSACHUSETTS 02142 US
CEO: John P. Butler
Employees: 167
Company Website: https://akebia.com/
Investor Relations: https://ir.akebia.com/
Phone: 16178712098
AKEBIA THERAPEUTICS INC / AKBA FAQ
What is the stock price of AKEBIA THERAPEUTICS INC today?
The current stock price of AKBA is 1.8 USD. The price decreased by -5.76% in the last trading session.
What is the ticker symbol for AKEBIA THERAPEUTICS INC stock?
The exchange symbol of AKEBIA THERAPEUTICS INC is AKBA and it is listed on the Nasdaq exchange.
On which exchange is AKBA stock listed?
AKBA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AKEBIA THERAPEUTICS INC stock?
9 analysts have analysed AKBA and the average price target is 7.31 USD. This implies a price increase of 306.11% is expected in the next year compared to the current price of 1.8. Check the AKEBIA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AKEBIA THERAPEUTICS INC worth?
AKEBIA THERAPEUTICS INC (AKBA) has a market capitalization of 392.72M USD. This makes AKBA a Small Cap stock.
How many employees does AKEBIA THERAPEUTICS INC have?
AKEBIA THERAPEUTICS INC (AKBA) currently has 167 employees.
What are the support and resistance levels for AKEBIA THERAPEUTICS INC (AKBA) stock?
AKEBIA THERAPEUTICS INC (AKBA) has a support level at 1.79 and a resistance level at 1.8. Check the full technical report for a detailed analysis of AKBA support and resistance levels.
Is AKEBIA THERAPEUTICS INC (AKBA) expected to grow?
The Revenue of AKEBIA THERAPEUTICS INC (AKBA) is expected to decline by -22.1% in the next year. Check the estimates tab for more information on the AKBA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AKEBIA THERAPEUTICS INC (AKBA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AKBA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AKBA, evaluating the profitability, health, valuation and growth aspects
- AKEBIA THERAPEUTICS INC (AKBA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AKEBIA THERAPEUTICS INC (AKBA) Sales and EPS estimates to see what analysts future expectations are.
- AKEBIA THERAPEUTICS INC (AKBA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AKEBIA THERAPEUTICS INC (AKBA) Insider and Institutional Ownership to learn about the owners and their transactions.
- AKEBIA THERAPEUTICS INC (AKBA) Stock Chart to make your own analysis
- AKEBIA THERAPEUTICS INC (AKBA) Latest news and press-releases to stay up to date.
Does AKEBIA THERAPEUTICS INC (AKBA) stock pay dividends?
AKBA does not pay a dividend.
When does AKEBIA THERAPEUTICS INC (AKBA) report earnings?
AKEBIA THERAPEUTICS INC (AKBA) will report earnings on 2025-03-12, after the market close.
What is the Price/Earnings (PE) ratio of AKEBIA THERAPEUTICS INC (AKBA)?
AKEBIA THERAPEUTICS INC (AKBA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.23).
What is the Short Interest ratio of AKEBIA THERAPEUTICS INC (AKBA) stock?
The outstanding short interest for AKEBIA THERAPEUTICS INC (AKBA) is 6.99% of its float. Check the ownership tab for more information on the AKBA short interest.
AKBA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AKBA. When comparing the yearly performance of all stocks, AKBA is one of the better performing stocks in the market, outperforming 81.99% of all stocks.
AKBA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AKBA. Both the profitability and financial health of AKBA have multiple concerns.
AKBA Financial Highlights
Over the last trailing twelve months AKBA reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 28.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.2% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AKBA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to AKBA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -11.72% and a revenue growth -22.1% for AKBA